HMGB1 and in situ carcinoma: Mechanistically, BG blocked HMGB1 nuclear export in ischemic brains, thereby decreasing HMGB1 levels in serum and lungs, and disrupting inflammatory cross-talk.<h4>Discussion</h4>These findings highlight BG's unique capacity to concurrently mitigate cerebral injury and secondary ALI by targeting the JAK2/STAT3 axis, offering a safe, multi-targeted strategy against CIS-related complications.